---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-016879"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:29:30.330145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q1 YUTIQ revenue up 60% to $7.4M; DAVIO 2 top-line data on track for Q4 2023

## Summary
- YUTIQ net product revenue $7.4M, up 60% YoY; customer demand 930 units (+43% YoY).
- Net loss $21.2M ($0.56/share); cash and investments $122.5M, down from $144.6M at Dec 31, 2022.
- Phase 2 DAVIO 2 trial for wet AMD fully enrolled (160 patients, oversubscribed); topline data expected Q4 2023.
- Phase 2 PAVIA trial for NPDR enrollment accelerated to 60 patients; data expected H1 2024; Phase 3 initiation advanced.
- Leased 40,000 sq ft manufacturing facility in Northbridge, MA; awarded $1.9M state/local grants; cash runway into H2 2024.

## SEC filing metadata
- accession: 0000950170-23-016879
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017023016879/0000950170-23-016879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017023016879/eypt-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-016879
- JSON: https://secwatch.observer/filing/0000950170-23-016879.json
- Plain text: https://secwatch.observer/filing/0000950170-23-016879.txt

## Key facts
- Earnings Releases
  EyePoint, Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended March 31, 2023 and highlighted recent corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017023016879/0000950170-23-016879-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.